Nasr AB, Ponnala D, Sagurthi SR, Kattamuri RK, Marri VK, Gudala S, Lakkaraju C, Bandaru S, Nayarisseri A. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions.
Bioinformation 2015;
11:307-15. [PMID:
26229292 PMCID:
PMC4512006 DOI:
10.6026/97320630011307]
[Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 06/28/2015] [Accepted: 06/29/2015] [Indexed: 12/14/2022] Open
Abstract
Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, proliferation and angiogenesis. mTOR signaling is
frequently hyper activated in a broad spectrum of human cancers thereby making it a potential drug target. The current drugs
available have been successful in inhibiting the mTOR signaling, nevertheless, show low oral bioavailability and suboptimal
solubility. Considering the narrow therapeutic window of the available inhibitors, through computational approaches, the present
study pursues to identify a compound with optimal oral bioavailability and better solubility properties in addition ensuing high
affinity between FKBP12 and FRB domain of mTOR. Current mTOR inhibitors; Everolimus, Temsirolimus Deforolimus and
Echinomycin served as parent molecules for similarity search with a threshold of 95%. The query molecules and respective similar
molecules were docked at the binding cleft of FKBP12 protein. Aided by MolDock algorithm, high affinity compounds against
FKBP12 were retrieved. Patch Dock supervised protein-protein interactions were established between FRB domain of mTOR and
ligand (query and similar) bound and free states of FKBP12. All the similar compounds thus retrieved showed better solubility
properties and enabled better complex formation of mTOR and FKBP12. In particular Everolimus similar compound PubChem ID:
57284959 showed appreciable drugs like properties bestowed with better solubility higher oral bioavailability. In addition this
compound brought about enhanced interaction between FKBP12 and FRB domain of mTOR. In the study, we report Everolimus
similar compound PubChem ID: 57284959 to be potential inhibitor for mTOR pathway which can overcome the affinity and
solubility concerns of current mTOR drugs.
Collapse